Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

Bone Marrow Transplantation

Volumn 33, Issue 8, 2004, Pages 823-828

  Lee, Choon Kee ^a   Zangari, M ^a   Barlogie, B ^a   Fassas, A ^a   van Rhee, F ^a   Thertulien, R ^a   Talamo, G ^a   Muwalla, F ^a   Anaissie, E ^a   Hollmig, K ^a   Tricot, G ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Multiple myeloma; Renal failure; Stem cell transplantation

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; MELPHALAN; MYELOABLATIVE AGENT; STEROID; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; BACTERIAL INFECTION; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC ENCEPHALOPATHY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYCOSIS; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RENAL DIALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 11144357978     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704440     Document Type: Article

References (19)

1. Knudsen LM, Hippe E, Hjorth M et al. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207-212.
2. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175-181.
3. Pichette V. Querin S, Desmeules M et al. Renal function recovery in end-stage renal disease. Am J Kidney Dis 1993; 22: 398-402.
4. Rota S, Mougenot B, Baudouin B et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine 1987; 66: 126-137.
5. Komatsuda A, Wakui H, Ohtani H et al. Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long-term chemotherapy. Am J Kidney Dis 2000; 35: E9.
6. Pozzi C, Fogazzi GB, Banfi G et al. Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995; 43: 281-287.
7. Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662-3670.
8. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822-829.
9. National Cancer Institute: Cancer Therapy Evaluation Program: Common Toxicity Criteria, version 2, Bethesda, MD, National Cancer Institute, April 30, 1999.
10. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
11. Hintze JL. Number Cruncher Statistical System 2001. NCSS Kaysville, UT.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. Journal of the American Statistical Association 1958; 53: 457-481.
13. Collett D. Modeling Survival Data in Medical Research. Chapman & Hall: London, 1994.
14. Lee CK, Barlogie B, Zangari ME et al. D.T.PACE, an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732-2739.
15. Fassas AB, Spencer T, Desikan R et al. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol 2002; 119: 164-168.
16. Barlogie B, McCoy J, Shaughnessy J et al. Total therapy II (TT II) for newly diagnosed multiple myeloma (MM): preliminary data on feasibility and efficacy in the first 231 enrolled patients; Comparison with Predecessor Trial Total Therapy I (TT I) (N = 231). Blood 2001; 98: 683 (abstract 2857).
17. Blade J, Fernandez-Llama P, Bosch F et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889-1893.
18. Torra R, Blade J, Cases A et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854-859.
19. Tricot G, Alberts DS, Johnson C et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947-952.